MX291518B - Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria. - Google Patents

Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria.

Info

Publication number
MX291518B
MX291518B MXPA06011940A MX291518B MX 291518 B MX291518 B MX 291518B MX PA06011940 A MXPA06011940 A MX PA06011940A MX 291518 B MX291518 B MX 291518B
Authority
MX
Mexico
Prior art keywords
depression
patients
prevention
treatment
fatty acids
Prior art date
Application number
Other languages
English (en)
Inventor
Rainer Oelze
Cees-Nico Verboom
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of MXPA06011940A publication Critical patent/MXPA06011940A/es
Publication of MX291518B publication Critical patent/MX291518B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA06011940 2004-04-16 2005-04-15 Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria. MX291518B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101578 2004-04-16
PCT/EP2005/004031 WO2005110393A1 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Publications (2)

Publication Number Publication Date
MXPA06011940A MXPA06011940A (es) 2006-12-15
MX291518B true MX291518B (es) 2011-10-31

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011940 MX291518B (es) 2004-04-16 2005-04-15 Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria.

Country Status (12)

Country Link
EP (1) EP1765319A1 (es)
JP (1) JP2007532605A (es)
CN (1) CN1942180A (es)
AU (1) AU2005244483B2 (es)
BR (1) BRPI0509878A (es)
CA (1) CA2504280A1 (es)
IL (1) IL178300A0 (es)
MX (1) MX291518B (es)
RU (1) RU2387448C2 (es)
UA (1) UA94693C2 (es)
WO (1) WO2005110393A1 (es)
ZA (1) ZA200607794B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
EE200300599A (et) * 2001-05-30 2004-02-16 Laxdale Limited Koensüüm Q ja EPA või muu asendamatu rasvhape

Also Published As

Publication number Publication date
WO2005110393A1 (en) 2005-11-24
RU2006140277A (ru) 2008-05-27
UA94693C2 (ru) 2011-06-10
CA2504280A1 (en) 2005-10-16
AU2005244483A1 (en) 2005-11-24
JP2007532605A (ja) 2007-11-15
AU2005244483B2 (en) 2011-06-09
ZA200607794B (en) 2008-05-28
CN1942180A (zh) 2007-04-04
EP1765319A1 (en) 2007-03-28
BRPI0509878A (pt) 2007-10-16
IL178300A0 (en) 2007-02-11
MXPA06011940A (es) 2006-12-15
RU2387448C2 (ru) 2010-04-27

Similar Documents

Publication Publication Date Title
MX2009003921A (es) Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.
PL1641918T3 (pl) Komórki poporodowe do zastosowania w leczeniu choroby serca i układu krążenia
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
EP2014292A3 (en) Fenoldopam for treatment of acute renal failure
EP1817050A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
IL177015B (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
EP1750734A4 (en) PROCESS FOR THE PREPARATION AND USE OF FIBRINOLYTIC ENZYMES FOR THE TREATMENT OF DISEASES
EP2497501A3 (en) Radionuclides for medical use
IL176027A0 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
EP1664775A4 (en) COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
MX291518B (es) Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria.
ZA200610297B (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
EP1819724A4 (en) BETA 2-GLYCOPROTEIN I COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
GB0511154D0 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status
GB Transfer or rights